New York GLP-1 Coverage Guide
New York offers strong Medicaid and commercial insurance coverage for GLP-1 medications, with active prior authorization pathways for both diabetes and obesity indications.
Medically reviewed by Dr. Sarah Chen, PharmD • Last updated April 2026
Medicaid Status
Medicaid coverage is available for GLP-1 medications in this state.
Medicare Eligibility
Medicare Part D may cover GLP-1 medications for eligible indications.
Coverage Overview
New York State provides some of the most comprehensive GLP-1 medication access in the country. Medicaid covers GLP-1s for both Type 2 diabetes and obesity management, commercial insurers increasingly include anti-obesity medications in their formularies, and the state’s consumer protection laws give patients strong appeal rights when coverage is denied. New York’s high cost of living also means more residents qualify for Medicaid under income thresholds than in lower-cost states.
New York Medicaid
NY Medicaid covers GLP-1 medications for both Type 2 diabetes and chronic weight management (obesity), making it one of the most favorable state Medicaid programs for GLP-1 access. Coverage is administered through managed care plans:
- Healthfirst — covers semaglutide and tirzepatide products for both diabetes and obesity with prior authorization
- Fidelis Care — covers GLP-1s with PA; preferred formulary agents may vary by quarter
- MetroPlus Health Plan — covers for NYC residents enrolled in Medicaid managed care
- EmblemHealth (GHI/HIP) — covers GLP-1s with step therapy requirements (typically metformin first for diabetes patients)
- Molina Healthcare of New York — covers with PA and documented medical necessity
Income thresholds for NY Medicaid: Individuals earning up to 138% of the Federal Poverty Level ($20,783/year for a single adult in 2026) qualify. New York also offers the Essential Plan for individuals earning up to 250% FPL ($37,650/year) — these plans also cover GLP-1 medications with low or no copays.
How to apply: Visit nystateofhealth.ny.gov (NY State of Health marketplace), call 1-855-355-5777, or visit your local Department of Social Services office. Processing typically takes 10–30 days, and coverage can be retroactive to the application date.
Commercial Insurance
New York’s commercial insurance market offers above-average GLP-1 coverage:
- Empire BlueCross BlueShield — covers GLP-1s for diabetes; increasing number of employer plans include obesity coverage. Large group plans are more likely to cover Wegovy and Zepbound.
- Aetna (NY) — diabetes coverage standard; obesity coverage expanding through employer plan additions in 2025–2026.
- UnitedHealthcare (NY) — varies by employer. NY-based large employers (finance, tech, media) increasingly include anti-obesity medication coverage as a competitive benefits offering.
- Cigna (NY) — diabetes coverage standard; weight management coverage plan-dependent.
- Oscar Health — as a NY-based insurer popular with individual and small group plans, Oscar has been early to include GLP-1 coverage for weight management.
New York’s insurance regulations require plans to cover “medically necessary” treatments, which can support GLP-1 coverage appeals when clinical criteria are met.
Eligibility Requirements
- BMI ≥ 30 (obesity diagnosis) or BMI ≥ 27 with at least one weight-related comorbidity (hypertension, Type 2 diabetes, sleep apnea, dyslipidemia, cardiovascular disease)
- Prior authorization from your prescribing physician with clinical documentation
- Documented lifestyle modification attempts (3–6 months, varies by insurer)
- New York State residency with valid enrollment in your plan
- Step therapy may be required for some plans (trying one GLP-1 before another, or metformin before GLP-1 for diabetes patients)
Appeals Process
New York has among the strongest patient appeal protections in the country:
- Internal appeal: File within 180 days of denial. Insurers must respond within 30 days (72 hours for urgent cases). New York requires insurers to inform you of your appeal rights in writing with every denial.
- External appeal: If internal appeal is denied, file an external appeal with the NY Department of Financial Services (DFS). An independent reviewer examines your case. File at dfs.ny.gov or call 1-800-400-8882. There is no cost to file.
- NY-specific advantage: New York law requires external review decisions to be binding on the insurer. The external reviewer evaluates medical necessity independently, and overturn rates for medication denials in NY are among the highest nationally — approximately 50–60%.
- Documentation tips: Include physician letter with specific clinical rationale, BMI history, comorbidity documentation, prior treatment attempts, and relevant clinical trial data.
Telehealth and Cash-Pay Options
For uninsured New Yorkers or those whose plans don’t cover GLP-1s for obesity:
- Manufacturer programs: NovoCare (Wegovy Pill at $149/month, injectable Wegovy at $349/month), LillyDirect (Zepbound at $299–449/month)
- Telehealth: All major platforms operate in New York — Hims, Ro (headquartered in NYC), Found, Calibrate, Noom Med (headquartered in NYC)
- New York’s telehealth laws are fully permissive for GLP-1 prescribing via video consultation